On July 9, 2026, Alex R. Thurman, the Senior Vice President and Chief Financial Officer of Glaukos Corp (NASDAQ: GKOS), executed a series of transactions involving the company's common stock. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan, which was initially adopted on December 15, 2025. This plan allowed for the systematic buying and selling of company shares without raising concerns regarding insider trading or market timing.
Mr. Thurman's activities on July 9, 2026, began with the acquisition of 10,000 shares of Glaukos common stock. These shares were obtained through the exercise of stock options at a conversion price of $38.68 per share, resulting in a total cost of $386,800. The options exercised were part of a grant that vests over a four-year period. Specifically, 25% of the grant vests on the first anniversary of the grant date, with the remaining portion vesting in equal monthly installments over the subsequent three years. These particular options were scheduled to expire on October 6, 2026.
Immediately following the exercise of these options, Mr. Thurman sold the 10,000 shares at a price of $155.00 per share. This sale generated a total of $1,550,000. The timing of these transactions is particularly notable given that Glaukos shares were trading near their 52-week high of $156.60 at the time, with the stock closing at $152.72. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value, placing it among companies on the Most Overvalued list.
Following these transactions, Mr. Thurman's direct holdings in Glaukos common stock totaled 43,681 shares. This figure includes 5,230 restricted stock units that have not yet vested or been delivered to him. The CFO's continued ownership, even after substantial sales, indicates ongoing involvement in the company's equity structure.
In other recent developments, Glaukos Corporation has been the focus of several analyst updates and clinical milestones. William Blair reiterated its Outperform rating on Glaukos, following a proposed local coverage determination on its iDose product. Discussions regarding this determination have recently concluded. Piper Sandler also maintained an Overweight rating and a $165.00 price target after surveying U.S. eye specialists. These specialists suggested that potential regulatory impacts could pose a 25-30% headwind to future iDose volumes.
In parallel, Glaukos announced the completion of patient enrollment in its Phase 2 study for GLK-321, a treatment for Demodex blepharitis utilizing the iLution platform. Needham raised its price target for Glaukos to $150 from $136, citing a positive outlook on corneal treatment. However, the firm noted mixed feedback on conversion to approvals. Stifel reiterated a Buy rating with a $170.00 price target after a regulatory meeting about the iDose LCD device. During this meeting, major medical societies expressed support for potential changes.
These developments highlight ongoing interest and activity around Glaukos's product pipeline and regulatory landscape. The company's stock performance and analyst sentiment reflect the complex interplay between clinical progress, regulatory decisions, and market valuation. Investors are closely monitoring these factors as they assess the potential risks and opportunities associated with Glaukos's future growth.